Home » Stocks » XTLB

XTL Biopharmaceuticals Ltd. (XTLB)

Stock Price: $3.36 USD 0.09 (2.75%)
Updated Jun 18, 2021 4:00 PM EDT - Market closed
Market Cap 18.19M
Revenue (ttm) n/a
Net Income (ttm) -2.95M
Shares Out 5.28M
EPS (ttm) -0.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 18
Last Price $3.36
Previous Close $3.27
Change ($) 0.09
Change (%) 2.75%
Day's Open 3.42
Day's Range 3.25 - 3.55
Day's Volume 44,304
52-Week Range 1.23 - 6.11

News

There are no news available yet.

About XTLB

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies ... [Read more...]

Industry
Biotechnology
IPO Date
Sep 1, 2005
CEO
Joshua Levine
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
XTLB
Full Company Profile

Financial Performance

Financial Statements